Home / NewTech / The UAE is announcing the emergency use of the COVID-19 vaccine for healthcare workers, which is still in final testing

The UAE is announcing the emergency use of the COVID-19 vaccine for healthcare workers, which is still in final testing



Chinese drug giant Sinopharm began the third phase of trials of a Covid-19 vaccine in the United Arab Emirates in July. Emirates officials said the results were positive.

The UAE is announcing the emergency use of the COVID-19 vaccine for healthcare workers, which is still in final testing

Human trials with Gam-COVID-Vac Lyo ̵

1; the vaccine candidate from the Gamaleya Scientific Research Institute – are now complete

The UAE has announced that it will approve the emergency use of a coronavirus vaccine for healthcare workers that is still in the final stages of human trials.

“The vaccine will be available to our first defense heroes who are at highest risk of contracting the virus,” the National Emergency Crisis and Disaster Management Authority (NCEMA) tweeted Monday.

Chinese drug giant Sinopharm began the third phase of trials of a Covid-19 vaccine in the United Arab Emirates in July. Emirates officials said the results were positive.

“The clinical trials for the third phase will continue under the strict supervision of medical teams, following all measures to control the quality, safety and effectiveness of the vaccine,” said NCEMA.

“The results of clinical trials in our country are on the right track as all tests have been successful so far.”

NCEMA said the vaccine had been tested on 31,000 volunteers and only “mild and expected” side effects were reported, adding that 1,000 subjects with chronic diseases showed “no complications”.

The announcement on Monday came amid a spike in coronavirus cases in the UAE, whose daily toll hit an all-time high on Saturday as the country recorded 1,007 infections.

The Gulf state has confirmed more than 80,000 cases in total, including 401 deaths.

Sinopharm hopes that the vaccine will be approved by the end of the year.

The antibodies from his vaccine are expected to last between one and three years, although the end result will not be known until after the trials.

There are currently nine vaccine candidates in late-stage human trials around the world, although some have encountered recent obstacles. Pharmaceutical company AstraZeneca and Oxford University temporarily suspended clinical trials last week after a volunteer developed an unexplained disease.

Meanwhile, Russia announced last month that its vaccine, named “Sputnik V” after the Soviet-era satellite first launched in 1957, had already been approved.

This raised concern among Western scientists about the lack of safety data and warned that vaccination too quickly could be dangerous.


Source link